<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132732">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797978</url>
  </required_header>
  <id_info>
    <org_study_id>B-1210/173-002</org_study_id>
    <nct_id>NCT01797978</nct_id>
  </id_info>
  <brief_title>Methylene Blue in Severe Sepsis and Septic Shock</brief_title>
  <official_title>Infusion of Methylene Blue in Severe Sepsis and Septic Shock: Randomized, Single Blinded</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to see whether the intravenous administration of methylene blue improves the
      outcome in severe sepsis and septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mortality of septic shock is still high ranging from 30 to 50%. Vasopressor is the main
      part in managing septic shock, but the choice of vasopressor is still under-investigated,
      and area of uncertainty.

      The response to vasopressor is sometimes unsatisfactory, and in that case, the outcome of
      the patients is poor.

      Recently, small size clinical trial has investigated the effect of methylene blue (MB), and
      showed promising results. However, large sized phase III trial has not been performed yet.

      Large sized phase III clinical trial is needed to establish the effect of MB in septic
      shock.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>within 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasopressor dependent period</measure>
    <time_frame>within 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor index</measure>
    <time_frame>with in 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cardiac output (CO) and systemic vascular resistance (SVR)</measure>
    <time_frame>with in 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
    <description>EV1000 (Edwards inc.) will be used to see the cardiac output and systemic vascular resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU (LOSICU)</measure>
    <time_frame>with in 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOS in hospital</measure>
    <time_frame>with in 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital mortality</measure>
    <time_frame>with in 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple organ failure (SOFA)</measure>
    <time_frame>with in 28 days of diagnosis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NO level</measure>
    <time_frame>before and after infusion of MB, 24hrs, 48hrs later</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine level (IL-6, 10, tumor necrosis factor -alpha)</measure>
    <time_frame>before and after infusion of MB, 24hrs, 48hrs later</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Intravenous methylene blue administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline administration instead of methylene blue</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous methylene blue administration</intervention_name>
    <description>Initial history taking and physical examination --&gt; enrollment --&gt; 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs</description>
    <arm_group_label>Intravenous methylene blue administration</arm_group_label>
    <other_name>methylene blue administration</other_name>
    <other_name>MB administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock meeting the criteria of 2012 surviving sepsis campaign

          -  Need the norepinephrine of over 0.2microgram/kg/min

        Exclusion Criteria:

          -  Pregnancy

          -  Less than 18 years old

          -  Immunosuppressant patients (e.g. on steroid medication, active anti-cancer
             chemotherapeutic agent, etc.)

          -  Declined consents

          -  glucose-6-phosphate dehydrogenase deficiency

          -  Medication of Serotonin modulator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyuseok Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Professor, department of emergency medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyuseok Kim, MD</last_name>
    <phone>+82-31-787-7572</phone>
    <email>dremkks@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chanjong Park, MD</last_name>
    <phone>+82-10-3902-3291</phone>
    <email>mickeyp@snubh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyeongi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyuseok Kim, MD</last_name>
      <phone>+82-31-787-7572</phone>
      <email>dremkks@snubh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyuseok Kim</last_name>
      <phone>+82-31-787-7572</phone>
      <email>dremkks@snubh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG - SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyuseok Kim</last_name>
      <phone>+82-31-787-7572</phone>
      <email>dremkks@snubh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Methylene blue</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
